Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group.

N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.

2.

A Late Case of Ischemic Cerebral Event after Resection of a Left Atrial Myxoma.

Lafleur R, Watkowska J, Zhou G, Alcide P, Saint-Jacques H.

Case Rep Neurol. 2016 May 24;8(2):97-101. doi: 10.1159/000444388. eCollection 2016 May-Aug.

3.

Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.

Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Steering Committee & Investigators; ROCKET AF Steering Committee Investigators.

J Am Heart Assoc. 2016 Mar 8;5(3):e002197. doi: 10.1161/JAHA.115.002197.

4.

Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).

Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA; ROCKET AF Steering Committee and Investigators.

Circulation. 2014 Jul 8;130(2):138-46. doi: 10.1161/CIRCULATIONAHA.113.005008. Epub 2014 Jun 3.

5.

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.

Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W; ROCKET AF Steering Committee Investigators.

Lancet Neurol. 2012 Apr;11(4):315-22. doi: 10.1016/S1474-4422(12)70042-X. Epub 2012 Mar 7.

PMID:
22402056
6.

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators.

N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.

7.

Early versus delayed, provisional eptifibatide in acute coronary syndromes.

Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK; EARLY ACS Investigators.

N Engl J Med. 2009 May 21;360(21):2176-90. doi: 10.1056/NEJMoa0901316. Epub 2009 Mar 30.

8.

Home use of automated external defibrillators for sudden cardiac arrest.

Bardy GH, Lee KL, Mark DB, Poole JE, Toff WD, Tonkin AM, Smith W, Dorian P, Packer DL, White RD, Longstreth WT Jr, Anderson J, Johnson G, Bischoff E, Yallop JJ, McNulty S, Ray LD, Clapp-Channing NE, Rosenberg Y, Schron EB; HAT Investigators.

N Engl J Med. 2008 Apr 24;358(17):1793-804. doi: 10.1056/NEJMoa0801651. Epub 2008 Apr 1.

9.

Acute coronary syndrome critical pathway: chest PAIN caremap: a qualitative research study--provider-level intervention.

Saint-Jacques H, Burroughs VJ, Watkowska J, Valcarcel M, Moreno P, Maw M.

Crit Pathw Cardiol. 2005 Sep;4(3):145-60. doi: 10.1097/01.hpc.0000175896.05417.5e.

PMID:
18340201
10.

The PAIN pathway as a tool to bridge the gap between evidence and management of acute coronary syndrome.

Herzog E, Saint-Jacques H, Rozanski A.

Crit Pathw Cardiol. 2004 Mar;3(1):20-4. doi: 10.1097/01.hpc.0000116583.24833.ce.

PMID:
18340134
11.

Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease.

Becker RC, Alexander JH, Dyke C, Huang Y, Saint-Jacques H, Hasselblad V, Harrington RA, Bovill EG; XaNADU-1B Investigators.

Thromb Res. 2006;117(4):439-46.

PMID:
15882894
12.

Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.

Alexander JH, Dyke CK, Yang H, Becker RC, Hasselblad V, Zillman LA, Kleiman NS, Hochman JS, Berger PB, Cohen EA, Lincoff AM, Saint-Jacques H, Chetcuti S, Burton JR, Buergler JM, Spence FP, Shimoto Y, Robertson TL, Kunitada S, Bovill EG, Armstrong PW, Harrington RA; XaNADU-PCI PILOT Investigators.

J Thromb Haemost. 2004 Feb;2(2):234-41.

13.

Glycoprotein receptor inhibitors in the management of acute coronary syndromes.

Saint-Jacques H, Harrington AR.

Curr Cardiol Rep. 2002 Jul;4(4):301-12. Review.

PMID:
12052269

Supplemental Content

Loading ...
Support Center